Bayesian variable selection using partially observed categorical prior information in fine-mapping association studies

Genet Epidemiol. 2019 Sep;43(6):690-703. doi: 10.1002/gepi.22213. Epub 2019 Jul 12.

Abstract

Several methods have been proposed to allow functional genomic information to inform prior distributions in Bayesian fine-mapping case-control association studies. None of these methods allow the inclusion of partially observed functional genomic information. We use functional significance (FS) scores that combine information across multiple bioinformatics sources to inform our effect size prior distributions. These scores are not available for all single-nucleotide polymorphisms (SNPs) but by partitioning SNPs into naturally occurring FS score groups, we show how missing FS scores can easily be accommodated via finite mixtures of elicited priors. Most current approaches adopt a formal Bayesian variable selection approach and either limit the number of causal SNPs allowed or use approximations to avoid the need to explore the vast parameter space. We focus instead on achieving differential shrinkage of the effect sizes through prior scale mixtures of normals and use marginal posterior probability intervals to select candidate causal SNPs. We show via a simulation study how this approach can improve localisation of the causal SNPs compared to existing mutli-SNP fine-mapping methods. We also apply our approach to fine-mapping a region around the CASP8 gene using the iCOGS consortium breast cancer SNP data.

Keywords: Bayesian; fine mapping; missing data; prior information; variable selection.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Bayes Theorem*
  • Biomarkers, Tumor / genetics*
  • Breast Neoplasms / genetics*
  • Case-Control Studies
  • Chromosome Mapping
  • Computer Simulation
  • Female
  • Genetic Association Studies*
  • Humans
  • Models, Theoretical*
  • Polymorphism, Single Nucleotide*

Substances

  • Biomarkers, Tumor